12-Month Data from Surmodics’ TRANSCEND Trial Presented at LINC 2021 Event
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Abbott Labs (ABT) PT Raised to $140 at Cowen
January 27, 2021 4:24 PM ESTCowen analyst Joshua Jennings raised the price target on Abbott Labs (NYSE: ABT) to $140.00 (from $113.00) while maintaining a Outperform rating.
The analyst comments "ABT finished 2020 with 28% organic sales growth and guided to 2021 EPS growth of more than 35%, which still looks conservative. We have... More
